Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UF-KURE19 CAR-T Cells in B Cell Non-Hodgkin Lymphomas
NCT05400109Phase 1Active, not recruiting
- Start
- Apr 2023
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UF-KURE19 in non-Hodgkin lymphoma (NHL). Primary endpoints: Recommended dose(s) of UF-KURE19 CAR-T Cells at 28 days, Toxicities associated with the target dose of UF-KURE19 CAR-T Cells at 12 months and 4 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
UF-KURE19
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05400109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400109.